FLORIDA BOARD OF PHARMACY
PSYCHIATRIC PHARMACIST
CERTIFICATION EXAM WITH ACTUAL
QUESTIONS AND VERIFIED ANSWERS,
PLUS EXPLAINED RATIONALES/EXPERT
VERIFIED FOR GUARANTEED 100% PASS
2026/LATEST UPDATE/INSTANT
DOWNLOAD PDF
1. Major Depressive Disorder — Treatment Selection
A 34-year-old patient with major depressive disorder has taken sertraline
200 mg/day for 10 weeks with excellent adherence. The patient reports
approximately 20% improvement in depressive symptoms but continues
to have marked anhedonia, low energy, impaired concentration, and
hypersomnia. There is no psychosis, mania, substance intoxication, or
suicidal plan. Which pharmacotherapeutic strategy is most appropriate?
A. Continue sertraline at 200 mg/day indefinitely because maximal
response may require 6 months
B. Add a second SSRI to sertraline
C. Switch to or augment with an antidepressant having a complementary
mechanism, such as bupropion, based on the clinical profile
D. Discontinue sertraline abruptly and initiate phenelzine the following
day
E. Add a benzodiazepine as the primary long-term antidepressant
strategy
Answer: C. Switch to or augment with an antidepressant having a
complementary mechanism, such as bupropion, based on the clinical
profile
1
,Rationale: A patient who has had an adequate dose, duration, and
adherence but only a partial response may benefit from augmentation
or switching. Bupropion can be particularly attractive when residual
hypersomnia, low energy, and concentration difficulties predominate
because it is generally activating and has relatively low sexual adverse-
effect burden. Combining two SSRIs is generally not preferred
because it offers limited mechanistic advantage and increases
serotonergic toxicity risk. Abrupt antidepressant discontinuation is
inappropriate. Benzodiazepines do not treat the core depressive
disorder and carry dependence and cognitive risks.
2. Bipolar Disorder — Antidepressant Risk
A 29-year-old patient with bipolar I disorder is stabilized on lithium.
The patient develops a severe depressive episode without psychotic
features. Which statement regarding antidepressant therapy is most
accurate?
A. Antidepressant monotherapy is routinely preferred
B. Antidepressants should always be combined with an antipsychotic but
never lithium
C. Antidepressant use should be individualized because of concern for
treatment-emergent mania or mood destabilization
D. Fluoxetine is contraindicated under all circumstances in bipolar
depression
E. Bupropion invariably causes mania and should never be considered
Answer: C. Antidepressant use should be individualized because of
concern for treatment-emergent mania or mood destabilization
Rationale: Bipolar depression requires careful distinction from
unipolar depression. Antidepressant monotherapy in bipolar I
depression is generally avoided because of the potential for manic
switching and mood destabilization. When an antidepressant is
2
,considered, it is typically used with an appropriate mood-stabilizing
strategy and careful monitoring. No antidepressant is universally
guaranteed to be safe or universally contraindicated in every bipolar
patient.
3. Lithium Toxicity
A patient taking lithium 900 mg/day develops vomiting, coarse tremor,
ataxia, dysarthria, and confusion after several days of severe diarrhea.
Which mechanism best explains the increased risk of lithium toxicity?
A. Increased hepatic CYP3A4 inhibition
B. Reduced renal lithium clearance associated with volume depletion
C. Increased lithium metabolism by hepatic enzymes
D. Increased protein binding of lithium
E. Increased biliary elimination of lithium
Answer: B. Reduced renal lithium clearance associated with volume
depletion
Rationale: Lithium is primarily eliminated by the kidneys. Volume
depletion increases proximal tubular sodium and lithium reabsorption,
reducing lithium clearance and increasing serum concentrations.
Gastrointestinal losses can therefore precipitate toxicity. Neurologic
findings such as coarse tremor, ataxia, dysarthria, and confusion are
concerning for significant lithium toxicity.
4. Lithium and NSAIDs
A patient stabilized on lithium begins taking ibuprofen several times
daily for chronic back pain. Two weeks later, the patient develops
nausea and worsening tremor. What is the most appropriate explanation?
3
, A. Ibuprofen increases hepatic metabolism of lithium
B. NSAIDs can reduce renal lithium clearance and increase lithium
concentrations
C. Lithium induces ibuprofen toxicity by CYP inhibition
D. Ibuprofen irreversibly binds lithium in plasma
E. The interaction occurs only with aspirin
Answer: B. NSAIDs can reduce renal lithium clearance and increase
lithium concentrations
Rationale: Many NSAIDs can reduce renal prostaglandin synthesis,
alter renal blood flow, and decrease lithium clearance, potentially
increasing serum lithium concentrations. Patients receiving lithium
should be monitored carefully when NSAIDs are initiated,
discontinued, or used chronically. The interaction is not limited to one
NSAID.
5. Valproate in Pregnancy
A woman with bipolar disorder who is capable of becoming pregnant is
taking valproate for maintenance therapy. Which concern is most
clinically important?
A. Valproate has no clinically meaningful fetal effects
B. Valproate is associated with significant teratogenic and
neurodevelopmental risks
C. Valproate is safer than all alternatives during pregnancy
D. Valproate causes fetal hypoglycemia but no structural abnormalities
E. Valproate is preferred specifically because it prevents neural-tube
defects
Answer: B. Valproate is associated with significant teratogenic and
neurodevelopmental risks
4
PSYCHIATRIC PHARMACIST
CERTIFICATION EXAM WITH ACTUAL
QUESTIONS AND VERIFIED ANSWERS,
PLUS EXPLAINED RATIONALES/EXPERT
VERIFIED FOR GUARANTEED 100% PASS
2026/LATEST UPDATE/INSTANT
DOWNLOAD PDF
1. Major Depressive Disorder — Treatment Selection
A 34-year-old patient with major depressive disorder has taken sertraline
200 mg/day for 10 weeks with excellent adherence. The patient reports
approximately 20% improvement in depressive symptoms but continues
to have marked anhedonia, low energy, impaired concentration, and
hypersomnia. There is no psychosis, mania, substance intoxication, or
suicidal plan. Which pharmacotherapeutic strategy is most appropriate?
A. Continue sertraline at 200 mg/day indefinitely because maximal
response may require 6 months
B. Add a second SSRI to sertraline
C. Switch to or augment with an antidepressant having a complementary
mechanism, such as bupropion, based on the clinical profile
D. Discontinue sertraline abruptly and initiate phenelzine the following
day
E. Add a benzodiazepine as the primary long-term antidepressant
strategy
Answer: C. Switch to or augment with an antidepressant having a
complementary mechanism, such as bupropion, based on the clinical
profile
1
,Rationale: A patient who has had an adequate dose, duration, and
adherence but only a partial response may benefit from augmentation
or switching. Bupropion can be particularly attractive when residual
hypersomnia, low energy, and concentration difficulties predominate
because it is generally activating and has relatively low sexual adverse-
effect burden. Combining two SSRIs is generally not preferred
because it offers limited mechanistic advantage and increases
serotonergic toxicity risk. Abrupt antidepressant discontinuation is
inappropriate. Benzodiazepines do not treat the core depressive
disorder and carry dependence and cognitive risks.
2. Bipolar Disorder — Antidepressant Risk
A 29-year-old patient with bipolar I disorder is stabilized on lithium.
The patient develops a severe depressive episode without psychotic
features. Which statement regarding antidepressant therapy is most
accurate?
A. Antidepressant monotherapy is routinely preferred
B. Antidepressants should always be combined with an antipsychotic but
never lithium
C. Antidepressant use should be individualized because of concern for
treatment-emergent mania or mood destabilization
D. Fluoxetine is contraindicated under all circumstances in bipolar
depression
E. Bupropion invariably causes mania and should never be considered
Answer: C. Antidepressant use should be individualized because of
concern for treatment-emergent mania or mood destabilization
Rationale: Bipolar depression requires careful distinction from
unipolar depression. Antidepressant monotherapy in bipolar I
depression is generally avoided because of the potential for manic
switching and mood destabilization. When an antidepressant is
2
,considered, it is typically used with an appropriate mood-stabilizing
strategy and careful monitoring. No antidepressant is universally
guaranteed to be safe or universally contraindicated in every bipolar
patient.
3. Lithium Toxicity
A patient taking lithium 900 mg/day develops vomiting, coarse tremor,
ataxia, dysarthria, and confusion after several days of severe diarrhea.
Which mechanism best explains the increased risk of lithium toxicity?
A. Increased hepatic CYP3A4 inhibition
B. Reduced renal lithium clearance associated with volume depletion
C. Increased lithium metabolism by hepatic enzymes
D. Increased protein binding of lithium
E. Increased biliary elimination of lithium
Answer: B. Reduced renal lithium clearance associated with volume
depletion
Rationale: Lithium is primarily eliminated by the kidneys. Volume
depletion increases proximal tubular sodium and lithium reabsorption,
reducing lithium clearance and increasing serum concentrations.
Gastrointestinal losses can therefore precipitate toxicity. Neurologic
findings such as coarse tremor, ataxia, dysarthria, and confusion are
concerning for significant lithium toxicity.
4. Lithium and NSAIDs
A patient stabilized on lithium begins taking ibuprofen several times
daily for chronic back pain. Two weeks later, the patient develops
nausea and worsening tremor. What is the most appropriate explanation?
3
, A. Ibuprofen increases hepatic metabolism of lithium
B. NSAIDs can reduce renal lithium clearance and increase lithium
concentrations
C. Lithium induces ibuprofen toxicity by CYP inhibition
D. Ibuprofen irreversibly binds lithium in plasma
E. The interaction occurs only with aspirin
Answer: B. NSAIDs can reduce renal lithium clearance and increase
lithium concentrations
Rationale: Many NSAIDs can reduce renal prostaglandin synthesis,
alter renal blood flow, and decrease lithium clearance, potentially
increasing serum lithium concentrations. Patients receiving lithium
should be monitored carefully when NSAIDs are initiated,
discontinued, or used chronically. The interaction is not limited to one
NSAID.
5. Valproate in Pregnancy
A woman with bipolar disorder who is capable of becoming pregnant is
taking valproate for maintenance therapy. Which concern is most
clinically important?
A. Valproate has no clinically meaningful fetal effects
B. Valproate is associated with significant teratogenic and
neurodevelopmental risks
C. Valproate is safer than all alternatives during pregnancy
D. Valproate causes fetal hypoglycemia but no structural abnormalities
E. Valproate is preferred specifically because it prevents neural-tube
defects
Answer: B. Valproate is associated with significant teratogenic and
neurodevelopmental risks
4
